Shu-Ping Lan

2.4k total citations
30 papers, 1.7k citations indexed

About

Shu-Ping Lan is a scholar working on Immunology, Rheumatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shu-Ping Lan has authored 30 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 7 papers in Rheumatology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shu-Ping Lan's work include Systemic Lupus Erythematosus Research (6 papers), Air Quality and Health Impacts (5 papers) and Drug Transport and Resistance Mechanisms (5 papers). Shu-Ping Lan is often cited by papers focused on Systemic Lupus Erythematosus Research (6 papers), Air Quality and Health Impacts (5 papers) and Drug Transport and Resistance Mechanisms (5 papers). Shu-Ping Lan collaborates with scholars based in United States, Canada and United Kingdom. Shu-Ping Lan's co-authors include John M. Lachin, Edmund J. Lewis, Lawrence G. Hunsicker, Richard D. Rohde, Kim Papp, Boni E. Elewski, Robert Wołk, Mandeep Kaur, Robert Bissonnette and W.C. Ports and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Annals of Internal Medicine.

In The Last Decade

Shu-Ping Lan

29 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shu-Ping Lan United States	20	742	737	375	305	290	30	1.7k
Grace S. Park United States	19	860 1.2×	409 0.6×	82 0.2×	119 0.4×	114 0.4×	31	1.4k
Jacques Pourrat France	18	241 0.3×	397 0.5×	441 1.2×	64 0.2×	88 0.3×	45	1.6k
Philippe Vanhille France	24	475 0.6×	346 0.5×	978 2.6×	126 0.4×	71 0.2×	52	2.4k
Burak Erer Türkiye	20	418 0.6×	446 0.6×	201 0.5×	215 0.7×	25 0.1×	66	1.8k
Ulrik Tarp Denmark	33	2.5k 3.4×	1.0k 1.4×	91 0.2×	193 0.6×	63 0.2×	74	3.4k
Fernand Mac–Moune Lai Hong Kong	35	482 0.6×	479 0.6×	1.5k 3.9×	463 1.5×	34 0.1×	98	3.5k
Isabelle Brochériou France	28	361 0.5×	464 0.6×	638 1.7×	297 1.0×	22 0.1×	129	2.4k
Þorvarður Jón Löve Iceland	24	1.6k 2.1×	1.6k 2.1×	46 0.1×	97 0.3×	372 1.3×	78	2.6k
Marie Holmqvist Sweden	25	1.3k 1.8×	436 0.6×	38 0.1×	108 0.4×	198 0.7×	70	2.4k
M. A. Ogryzlo Canada	18	1.1k 1.5×	675 0.9×	183 0.5×	108 0.4×	21 0.1×	36	1.8k

Countries citing papers authored by Shu-Ping Lan

Since Specialization

Citations

This map shows the geographic impact of Shu-Ping Lan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu-Ping Lan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu-Ping Lan more than expected).

Fields of papers citing papers by Shu-Ping Lan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu-Ping Lan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu-Ping Lan. The network helps show where Shu-Ping Lan may publish in the future.

Co-authorship network of co-authors of Shu-Ping Lan

This figure shows the co-authorship network connecting the top 25 collaborators of Shu-Ping Lan. A scholar is included among the top collaborators of Shu-Ping Lan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu-Ping Lan. Shu-Ping Lan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Bo, Shu-Ping Lan, Jiaqiang Li, et al.. (2024). Digital image correlation in extreme conditions. Thin-Walled Structures. 205. 112589–112589. 16 indexed citations

Weinhold, Kent J., Jack F. Bukowski, Todd V. Brennan, et al.. (2018). Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clinical Immunology. 191. 10–20. 26 indexed citations

Merola, Joseph F., Boni E. Elewski, Svitlana Tatulych, et al.. (2017). Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 77(1). 79–87.e1. 73 indexed citations

Wołk, Robert, Ehrin J. Armstrong, Peter Riis Hansen, et al.. (2017). Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. Journal of clinical lipidology. 11(5). 1243–1256. 54 indexed citations

Feldman, Steven R., Diamant Thaçi, Melinda Gooderham, et al.. (2016). Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 75(6). 1162–1170.e3. 48 indexed citations

Papp, Kim, Alan Menter, Boni E. Elewski, et al.. (2015). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology. 173(4). 949–961. 256 indexed citations

Isaacs, John D., Andrea Zuckerman, Sriram Krishnaswami, et al.. (2014). Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Research & Therapy. 16(4). R158–R158. 37 indexed citations

Ports, W.C., Sairah Khan, Shu-Ping Lan, et al.. (2013). A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. British Journal of Dermatology. 169(1). 137–145. 163 indexed citations

Vincenti, Flavio, Stéphan Busque, Philip J. O’Connell, et al.. (2012). Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year. American Journal of Transplantation. 12(9). 2446–2456. 124 indexed citations

10.

Isaacs, John D., Chudy I. Nduaka, S. Krishnaswami, et al.. (2012). AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690,550). Annals of the Rheumatic Diseases. 71. 672–672. 2 indexed citations

11.

Lan, Shu-Ping, et al.. (1993). Irreproducibility of the Activity and Chronicity Indices Limits Their Utility in the Management of Lupus Nephritis. American Journal of Kidney Diseases. 21(4). 374–377. 87 indexed citations

12.

Levey, Andrew S., Shu-Ping Lan, Howard L. Corwin, et al.. (1992). Progression and Remission of Renal Disease in the Lupus Nephritis Collaborative Study. Annals of Internal Medicine. 116(2). 114–123. 105 indexed citations

13.

Lachin, John M. & Shu-Ping Lan. (1992). Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study. Controlled Clinical Trials. 13(1). 62–79. 14 indexed citations

14.

Pohl, Marc A., et al.. (1991). Plasmapheresis Does Not Increase the Risk for Infection in Immunosuppressed Patients with Severe Lupus Nephritis. Annals of Internal Medicine. 114(11). 924–929. 71 indexed citations

15.

Schwartz, Melvin M., Shu-Ping Lan, Stephen M. Bonsib, Gordon N. Gephardt, & Hari M. Sharma. (1989). Clinical Outcome of Three Discrete Histologic Patterns of Injury in Severe Lupus Glomerulonephritis. American Journal of Kidney Diseases. 13(4). 273–283. 48 indexed citations

16.

Grundy, Scott M., Shu-Ping Lan, & John M. Lachin. (1984). The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS).. Journal of Clinical Investigation. 73(4). 1156–1166. 21 indexed citations

17.

Phillips, James M., et al.. (1983). Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients With Cholelithiasis: the National Cooperative Gallstone Study. Hepatology. 3(2). 209–220. 31 indexed citations

18.

Lan, Shu-Ping, et al.. (1982). A study of acute respiratory disease in families exposed to different levels of Air pollution in the Great Salt Lake basin, Utah, 1971-1972 and 1972-1973.. Environmental Health Perspectives. 44. 165–174. 8 indexed citations

19.

Lan, Shu-Ping, et al.. (1982). Acute Respiratory Illness in Families Exposed to Nitrogen Dioxide Ambient Air Pollution in Chattanooga, Tennessee. Archives of Environmental Health An International Journal. 37(2). 75–80. 31 indexed citations

20.

Lan, Shu-Ping & Carl M. Shy. (1981). Effect of Air Pollution on Chronic Respiratory Disease in the New York City Metropolitan Area, 1972. Environmental Health Perspectives. 42. 203–203. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact